fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

Life sciences companies benefit from the ‘pharma carveout’ in Trump’s tariffs. But how long will it last?

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production back to the United States.

At life sciences incubator LabCentral, a change at the top in a challenging time
Founder Johannes Fruehauf is turning over the CEO reins to Maggie O’Toole, who was employee No. 1 when LabCentral launched in 2013.

Top vaccine official’s ouster sends biotech stocks tumbling
Moderna shares fell almost 9 percent in Monday trading, while other makers of vaccines and drugs like gene therapies saw their stocks drop, including Novavax, BioNTech, and Sarepta Therapeutics.

The US approved an Alzheimer’s drug. Seven patients subsequently died.
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s memory.

Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the stage for a new therapeutic option for patients with the rare disease.

Biogen to move its Cambridge headquarters in 2028
With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one.

Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was and whether it warranted making the drug available for patients facing a fatal disease with few other options.

Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

More Life Sciences Headlines

Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a disease-causing mutation.

Roche to open innovation center at new Harvard campus in Allston that could employ hundreds

Mayor Michelle Wu called the move a "major milestone" for the campus and neighborhood.

BOLD TYPES

Why were zebras parachuting from the rafters at a recent Celtics game?

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on Friday at the TD Garden.

Ginkgo further scales back Seaport real estate

The once fast-growing biotech firm is cutting its footprint again.

Thermo Fisher inks $4 billion deal to buy former 3M filtration business

Waltham-based Thermo is buying the business from Solventum, a Minnesota-based company that spun off from manufacturing conglomerate 3M roughly one year ago.

Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million

The cut-rate price reflects the Somerville-based biotech company’s tumble from soaring heights.

Shirley Leung

Trump is coming for ‘eds and meds.’ That’s a big problem for Massachusetts.

The strength of the Massachusetts economy comes down to one thing: brain power. Now our jobs, research, and talent pool could be vulnerable.

innovation economy

No more needles? Startups are testing patches to deliver weight-loss drugs and other medications.

Local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.